Pancreatic Cancer Research

ResearcherThreshold Pharmaceuticals (United States)No recent work listed

Charles P. Hart

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4440-726X; OpenAlex author ID A5042870042. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper

Papers 3

  1. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. Co-author DOI 10.1371/journal.pone.0155289↗
  2. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic ca… Last author DOI 10.1080/15384047.2014.1003005↗
  3. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0113586↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert J. Gillies · 2 shared papers, 2014–2016 · strength 0.11
  2. Pawel Swietach · 2 shared papers, 2014–2016 · strength 0.11
  3. Amanda F. Baker · 2 shared papers, 2014–2016 · strength 0.11
  4. Xiaomeng Zhang · 1 shared paper, 2016 · strength 0.07
  5. Jessica D. Sun · 1 shared paper, 2015 · strength 0.05
  6. Yan Wang · 1 shared paper, 2015 · strength 0.05
  7. Kate M. Bailey · 1 shared paper, 2014 · strength 0.04
  8. Xiaomeng Zhang · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.